APLS Apellis Pharmaceuticals, Inc.
APLS Apellis Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Reported the quarter ending 2026-03-31: revenue $268M, diluted EPS $0.15, net income $19M (the desk's provider cache). Across the print the stock moved -0.2% (close before → first close after).
full note →APLS research tape
4 dated scans, research, and events, newest first — the full record.